Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-Year results of a randomized clinical trial

Archives of Ophthalmology

Volumn 123, Issue 4, 2005, Pages 448-457

  Bressler, Neil M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; FLUORESCEIN; PLACEBO; PHOTOSENSITIZING AGENT; PORPHYRIN;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORTH AMERICA; OPHTHALMOSCOPY; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISORDER; COMPARATIVE STUDY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; RETINA FOVEA; RETINA MACULA DEGENERATION; SAFETY;

AGED; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOVEA CENTRALIS; HUMANS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; SAFETY; VISUAL ACUITY;

EID: 16844375997     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.4.448     Document Type: Article

References (17)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol. 1999;117:1329-1345.
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol. 2001;119:198-207.
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP Report No. 3. Arch Ophthalmol. 2002;120:1443-1454.
4. Rubin GS, Bressler NM. Effects of verteporfin therapy on contrast on sensitivity: results from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation - TAP Report No. 4. Retina. 2002;22:536-544.
5. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin In Photodynamic Therapy Report 2. Am J Ophthalmol. 2001;131:541-560.
6. Verteporfin Roundtable 2000 and 2001 Participants; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators; Verteporfin In Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002;22:6-18.
7. American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern: age-related macular degeneration. October 2001. Available at: http://www.aao.org/education/library/ppp/amd.new.cfm. Accessed February 3, 2005.
8. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol. 1991;109:1242-1257.
9. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP Report No. 2. Arch Ophthalmol. 2003;121:1253-1268.
10. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report No. 1. Am J Ophthalmol. 2003;136:407-418.
11. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830-841.
12. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44:2147-2154.
13. Henderson BW, Gollnick SO, Snyder JW, et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res. 2004;64:2120-2126.
14. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy for choroidal neovascularization due to age-related macular degeneration with verteporfin; results of a single treatment in a phase I and II study. Arch Ophthalmol. 1999;117:1161-1173.
15. Chow SC, Liu JP. Design and Analysis of Clinical Trials: Concepts and Methodologies. New York, NY: John Wiley & Sons Inc; 1998.
16. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Acute severe visual acuity decrease following photodynamic therapy with verteporfin: case reports from randomized clinical trials - TAP and VIP Report No. 3. Am J Ophthalmol. 2004;137:683-696.
17. Centers for Medicare and Medicaid Services (CMS), US Department of Health and Human Services. Decision Memo for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066R3). Available at: http://cms.hhs.gov/mcd/viewdecisionmemo.asp?id=101. Accessed February 3, 2005.